March 21th, 2011 - ERYtech Pharma reports that their positive results obtained with the project on Immunomodulation will be presented at the 6th International Symposium on the Clinical Use of Cellular Products, Erlangen (March 24-25, 2011).Immunomodulation is a promising therapeutic strategy dedicated to all conditions resulting from a dysfunction of the adaptive immune system. In such pathological conditions, the immune system either fails to react, or conversely, overreacts in the presence of antigens, leading to the development of an infection or a tumor. At the basis of immune reaction, dendritic cells and macrophages are the key antigen-presenting cells involved in the process initiation. One of the great challenges of Immunomodulation specifically lies in the selective targeting of these dendritic cells and macrophages to modulate the immune response. Making the cell targeting more selective indeed amounts to significantly optimize the therapeutic efficacy of a product...
[...]
...About ERYtech Pharma
ERYtech Pharma (Lyon, Philadelphia) is a specialty pharma company developing innovative therapeutic solutions based on its proprietary technology and expertise in the physiological properties of erythrocytes. The company addresses serious pathologies, orphan indications or unaddressed sub-populations of patients, particularly in the fields of hematology, cancer and metabolic diseases... ERYtech Pharma's Press Release -
